Timosaponin A3 can inhibit SREBP-1 and its targets, FASN and ACC, to reduce cell viability and increase cell cycle arrest and apoptosis of BxPC-3 cells and pancreatic cancer xenograft growth, which is independent in the Akt/GSK-3β pathway (171). Here, SREBF1 is linked to familial pancreatic carcinoma.